IMRX Latest Press Releases

-- October 26, 2026 --

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026 Globe Newswire 7:30 AM

-- October 2, 2026 --

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) Globe Newswire 9:00 AM

-- September 28, 2026 --

Immuneering Presents Data at 2026 AACR Conference on Pancreatic Cancer Supporting Atebimetinib's Mechanisms Designed to Extend Survival in Pancreatic Cancer Globe Newswire 7:30 AM

-- September 24, 2026 --

Immuneering to Present at the ESMO Congress 2026 Globe Newswire 7:30 AM

-- September 10, 2026 --

Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib's Dual Mechanism for Extended Survival Globe Newswire 7:30 AM

-- September 3, 2026 --

Immuneering to Participate in Upcoming Investor Conferences Globe Newswire 4:05 PM

-- August 26, 2026 --

Immuneering Comments on Today's FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients Globe Newswire 5:16 PM

-- August 5, 2026 --

Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates Globe Newswire 7:30 AM

-- July 21, 2026 --

Publication in Cancer Research Details Atebimetinib's Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition Globe Newswire 4:05 PM

-- July 17, 2026 --

Immuneering Corporation Announces Grants of Inducement Awards Globe Newswire 4:05 PM

-- July 6, 2026 --

Kalaris Appoints Laurie Keating to Board of Directors Globe Newswire 4:05 PM

-- June 15, 2026 --

Immuneering Appoints Andrew Gengos as Chief Financial Officer Globe Newswire 7:30 AM

-- June 11, 2026 --

Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Globe Newswire 7:30 AM

-- June 1, 2026 --

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO Globe Newswire 7:30 AM

Market Data Delayed 15 Minutes